Thursday, November 19, 2026

Pyxis Oncology, Inc. has released updated findings from its ongoing global Phase 1 monotherapy study of micvotabart pelidotin (MICVO) in patients with second-line and later recurrent/metastatic head and neck squamous cell carcinoma (2L+ R/M HNSCC). Based on an October 14, 2026 data cutoff, the trial recorded a confirmed objective response rate (cORR) of 39%, a disease control rate (DCR) of 94%, and a newly reported median duration of response (mDOR) of 9.2 months across 33 efficacy-evaluable patients. All patients in this group received 5.4 mg/kg intravenously once every three weeks, at a dose equivalent to or below the protocol’s dose cap.

Additional results showed a median progression-free survival (mPFS) of 6.7 months and a 12-month overall survival (OS) probability of 81%. On the safety side, the company reported no new cases of Grade 3 peripheral neuropathy. All six patients who had experienced Grade 3 peripheral neuropathy showed improvement, with five of the six improving to Grade 1 or better. Together, these findings support Pyxis Oncology’s plan to advance MICVO into the global Phase 3 Headliner trial in 2L+ R/M HNSCC, which is expected to begin in mid-2027.

Source link

Exit mobile version